New scholarships worth EUR 417,000 awarded by Bayer Foundation to promote international talents

BayerWith approximately EUR 417,000, the Bayer Science & Education Foundation is providing a record amount for 65 talented young people who wish to realize international study and vocational training projects. The new scholarship recipients are students of the natural sciences, agriculture and medicine, as well those training to become science teachers or young people from skilled non-academic professions. "We need dedicated and creative young scientists if we are to successfully shape the future. That's why with the Bayer Fellowship Program we are helping talented young people to participate in special projects abroad," says Kemal Malik, Bayer Management Board member responsible for Innovation.

Today's "Bayer Fellowship program" follows the tradition of the first company scholarships initiated back in 1923 by Dr. Carl Duisberg, at that time Managing Director of the Bayer Group. Duisberg is regarded as a pioneer in the intensive cooperation between industry and universities, as well as in corporate social responsibility. Explains Dr. Carl-Heinz Duisberg, member of the Scientific Committee of the Bayer Fellowship Program and youngest grandchild of the program's founder: "My grandfather wanted to provide the best development opportunities for young talents because he saw this as a means of ensuring long-term benefits for society. He is also quoted as saying 'We must spend every spare penny on science - it is the best investment we can make.'"

All scholarships underline the mission of the Bayer foundation to work with young people and the next generation of scientists and opinion-leaders and to strengthen interest in the major challenges facing our society, such as health and agriculture.

Alongside the Otto Bayer, Jozef Schell and Carl Duisberg scholarships, the Bayer Fellowship Program also includes the Kurt Hansen and Hermann Strenger scholarships. For the third time, the Bayer Science & Education Foundation offers an additional special budget for "Talents for Africa". The scholarships are targeted at students and vocational trainees in natural science and medical disciplines who would like to realize a particular foreign study project and require financial support for this. In addition to Germany-based applicants who would like to study abroad, the foundation supports scholarship recipients from outside of Germany who wish to realize a comparable project in Germany.

Academic disciplines receiving support this year include the life sciences, chemistry, agriculture as well as human and veterinary medicine, with a total of 56 scholarships being awarded. Three Kurt Hansen scholarship recipients are also receiving assistance for teacher training in the natural sciences. The scholarships in the academic sector are being supplemented by Hermann Strenger scholarships to support young people looking to gain initial work experience abroad as part of a non-academic training program. This year, six young people from Germany are being supported who are planning a period abroad as part of their commercial, technical or health profession training.

Thanks to the Bayer scholarships, 47 new fellows from Germany will start their projects in 18 different countries: Argentina, Australia, Brazil, Chile, Ethiopia, France, Gabon, Israel, Mexico, Nicaragua, Russian Federation, Rwanda, Spain, Sri Lanka, Sweden, Switzerland, United Kingdom and the United States. Another 18 new scholarship winners will be able to implement their individual projects in Germany, coming from: Austria, Bangladesh, Brazil, Canada, Egypt, Finland, Italy, Mexico, Morocco, Netherlands, Nigeria, Pakistan, Russian Federation, Singapore, Syria, Tunisia, Turkey and United Kingdom.

The Bayer Science & Education Foundation thus is launching the eleventh round of its funding program, which offers targeted support for scientific exchange and international work experience for young people. It targets creative, highly motivated and socially committed young people with above-average grades.

The next round of applications starts in June 2018.

More information is available on the Internet at www.bayer-foundations.com.

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]